In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.
first published: Jul 21, 2011 03:55 pm
A collection of the most-viewed Moneycontrol videos.

Live: Nifty recovers 100 pts from day's low, metals under pressure | Closing Bell

Govt to stick to the path of fiscal consolidation - Prof Dev, PMEC chairman

Budget 2026 expectations: Taxpayers eye higher standard deduction, home loan interest relief

Live: Will Nifty take a breather after 3-day rally amid mixed global cues | Opening Bell
You are already a Moneycontrol Pro user.